Thai drugmaker Siam Bioscience, owned by the country’s king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc’s COVID-19 vaccine, government data shows.
https://www.pharmalive.com/wp-content/uploads/2022/08/ReutersSiamBioscience8-25-2022.jpg7441200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-08-25 05:31:132022-08-25 11:44:51Thai king’s medical firm reports record profit after vaccine deal with AstraZeneca
